



BeneHold™ CHG Antimicrobial Adhesive Technology

Introducing a customizable antimicrobial skin-contact adhesive technology platform

An opportunity to deliver antimicrobial performance in skin-contact adhesive products from a leader in materials science

Chlorhexidine gluconate (CHG) was selected by Avery Dennison Medical as the antimicrobial of choice owing to its widespread use and acceptance as a skin antiseptic in hospital settings. The BeneHold CHG antimicrobial adhesive platform combines this effective antimicrobial agent with Avery Dennison Medical's well-established expertise in skin-contact adhesives, allowing for the development of unique products in a variety of medical applications with our partners.

Proprietary BeneHold™ CHG Antimicrobial Adhesive Technology

- Incorporates CHG directly into the adhesive
- Eliminates the need for an additional component to hold and deliver the antimicrobial
- Offers broad spectrum antimicrobial efficacy
- Allows for contact layer to remain transparent and thin
- Allows for full visualization of the site (when required for the application)
- Option to tailor adhesion and fluid management performance to meet application requirements
- Enables customization to meet user requirements

Applications

BeneHold CHG Antimicrobial Adhesive Technology can be customized for a variety of applications and performance requirements. In existing commercial products, it has been designed to address applications requiring long wear time and sustained antimicrobial efficacy up to 7 days.

- Vascular Access and Post-op dressings feature:
 - Sustained antimicrobial efficacy, throughout 7-day wear
 - Transparency for undisturbed site visualization
 - Manages low to moderate exudate without needing a pad
 - Waterproof
 - Barrier to external contaminants

Partnership Opportunities

- Currently seeking global marketing and distribution partners in vascular access and post-op dressings.
- Applications targeted for expansion:
 - We are looking to expand into additional applications outside of our current product lines with a development partnership. We will work closely with our partner to develop and commercialize new products utilizing our BeneHold CHG adhesive technology.
 - Current targets include:
 - Surgical
 - Negative pressure wound therapy
 - Advanced wound care
 - We are not limited to only these applications. If you have an idea for a product application outside of those listed, we would like to discuss partnership opportunities with you.

Check out our latest article, "Preliminary analysis of the antimicrobial activity of a postoperative wound dressing containing chlorhexidine gluconate against methicillin-resistant *Staphylococcus aureus* in an in vivo porcine incisional wound model" in the *American Journal of Infection Control*.

Partner with us to develop unique products with BeneHold™ CHG Antimicrobial Adhesive Technology. If you are interested in marketing and distributing our post-op dressing, vascular access dressings, or are interested in developing a new product for another medical application, connect with our team to learn more.

CONNECT WITH US FOR MORE INFORMATION!

Barbara Van Rymenam, Global Director, Innovation Platforms



mobile: +32 (0)497103233



email: barbara.van.rymenam@eu.averydennison.com



website www.medical.averydennison.com

©2021, Avery Dennison Corporation. Avery Dennison, BeneHold and the triangle logo are registered trademarks of Avery Dennison Corporation. All rights reserved. All other trademarks are the property of their respective owners. Eloquest Healthcare® and ReliaTect® are registered trademarks of Ferndale IP, Inc. BD and BD ChlorShield are property of Becton, Dickinson and Company. Products described may be covered under one or more pending or granted patents.

GBL-MKT-000092-C



Medical